Therapeutic Study of 177Lu-CTR-FAPI-targeted Nuclear Drugs in Advanced Metastatic Digestive Malignancies
The study investigates 177Lu-CTR-FAPI, a radiopharmaceutical targeting FAP, in patients with advanced metastatic gastrointestinal malignancies. Given the high unmet medical need in this patient population, successful outcomes could position 177Lu-CTR-FAPI as a novel therapeutic option in a competitive landscape dominated by traditional chemotherapy and emerging targeted therapies. The market for advanced GI malignancies is substantial, with increasing incidences of pancreatic and colorectal cancers. The trial's single-arm design may limit comparative efficacy claims, necessitating further studies for broader market acceptance. Diligence should focus on the safety profile and potential for combination therapies, as well as regulatory pathways in key markets.
Indication: Pancreatic Ductal Adenocarcinoma (PDAC)
Modality: small molecule
Target: Fibroblast Activation Protein (FAP)
Sponsor: Xijing Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Fibroblast Activation Protein (FAP)
View original source fields
Condition raw: Pancreatic Ductal Adenocarcinoma (PDAC), Adenocarcinoma of the Stomach, Colorectal Cancer Metastatic, Neuroendocrine Tumor (NET)
Condition normalized: Pancreatic Ductal Adenocarcinoma (PDAC), Adenocarcinoma of the Stomach, Colorectal Cancer Metastatic, Neuroendocrine Tumor (NET)
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Fibroblast Activation Protein (FAP)
Target normalized: Fibroblast Activation Protein (FAP)